Whim Syndrome

Healio compiled the most-read news in allergy, asthma and immunology posted in May.

X4 Pharmaceuticals has announced that the FDA approved Xolremdi as a treatment for warts, hypogammaglobulinemia, infections and myelokathexis, also known as WHIM, syndrome, a rare and chronic primary immunodeficiency.

The FDA has approved mavorixafor for treating warts, hypogammaglobulinemia, infections and myelokathexis — or WHIM — syndrome, a rare and chronic primary immunodeficiency, according to a press release from X4 Pharmaceuticals.